ReviewPreprint
This scoping review systematically mapped the published and registered evidence on Thymosin Beta-4 (TB4) and the related synthetic peptide TB-500 in tissue healing, regeneration, and musculoskeletal repair. Searching PubMed, Europe PMC, and ClinicalTrials.gov through March 2026, the authors identified 1,772 records and included 80 studies after screening. Key findings include: (1) the evidence base is heavily skewed toward in vitro and animal (preclinical) designs rather than human trials; (2) most research has examined TB4, while direct evidence on TB-500 was limited to a single included study; (3) the most studied tissue categories were wound/skin/soft tissue, vascular/endothelial, and ocular/corneal, with the strongest human evidence concentrated in ocular and wound-healing contexts; and (4) musculoskeletal-specific tissues—such as tendon, ligament, muscle, cartilage, and intervertebral disc—were comparatively underrepresented. The authors concluded that while the literature supports interest in several repair-related biological pathways, it remains unevenly distributed and largely preclinical, and does not yet provide a robust human evidence base for musculoskeletal applications. Scoping reviews do not perform meta-analyses or quality appraisal of individual studies, which limits causal conclusions.
Unknown journal · May 2026DOI ↗ Review
This narrative review examines the pharmacological mechanisms, safety profiles, and regulatory status of twelve peptides commonly marketed in sports medicine contexts, spanning both FDA-approved compounds (e.g., tesamorelin/Egrifta) and unapproved "gray market" substances (e.g., BPC-157, CJC-1295, TB-500, ipamorelin, and others). The authors note that while many unapproved peptides show promising tissue repair and metabolic effects in animal models, rigorous human safety and efficacy data are largely absent. The review highlights a growing direct-to-consumer gray market operating outside regulatory oversight and discusses the potential for serious patient harm. Notably, the authors address the placebo effect as a possible mediator of perceived peptide efficacy and examine how social media may amplify this effect. A clinician-oriented framework is proposed to guide evidence-based patient discussions about peptide use for musculoskeletal healing and athletic performance, including consideration of alternative treatments. Key limitations include the narrative (non-systematic) review methodology and the inherently limited and heterogeneous evidence base for most compounds discussed, particularly in human populations.
Sports medicine (Auckland, N.Z.) · Apr 2026DOI ↗ ReviewPreprint
This narrative review examines the pharmacological mechanisms, safety profiles, and regulatory status of twelve peptides commonly encountered in sports medicine and athletic performance contexts, including both approved agents (e.g., tesamorelin/Egrifta, sermorelin) and unapproved "gray market" compounds (e.g., BPC-157, CJC-1295, TB-500, ipamorelin, AOD-9604, FS-344, GHK-Cu, MOTS-C, SS-31, and thymosin beta-4). The authors note that while many unapproved peptides show promising tissue repair and metabolic outcomes in animal models, rigorous human safety and efficacy data remain scarce. The review highlights the emergence of a direct-to-consumer gray market operating outside regulatory oversight and the potential for serious patient harm. It further discusses the placebo effect as a potential mediator of perceived peptide efficacy, and how social media may amplify this effect. The authors provide a clinical framework to guide patient-provider discussions and promote evidence-based practice for musculoskeletal healing. Key limitations include the narrative (non-systematic) review design, reliance on preclinical literature for most unapproved compounds, and the absence of head-to-head human trials for the majority of agents discussed.
Unknown journal · Apr 2026DOI ↗ Review
This comprehensive narrative review examines nine therapeutic peptides with proposed applications in healthy aging and age-related conditions: tirzepatide (metabolic dysfunction), epitalon (telomere biology), GHK-Cu (dermal regeneration), BPC-157 and TB-500 (tissue repair), Semax (neuroprotection), CJC-1295 and ipamorelin (growth hormone modulation), and bremelanotide (sexual function). The authors searched PubMed, Scopus, and regulatory databases through January 2026, selecting 20 primary sources based on relevance and methodological quality. The review found that FDA-approved agents such as tirzepatide and bremelanotide have robust safety and efficacy data from large-scale trials, while investigational peptides such as epitalon, BPC-157, and TB-500 show promising signals primarily from preclinical and limited clinical studies. The authors highlight significant knowledge gaps, including the absence of long-term safety data for non-approved peptides, undefined optimal dosing regimens, unknown combination therapy effects, and lack of validated biomarkers for monitoring efficacy. The authors conclude that while therapeutic peptides offer mechanistically diverse approaches to aging hallmarks, investigational agents require rigorous clinical trial validation before clinical adoption. As a narrative review, findings are subject to selection bias and do not represent a quantitative synthesis of evidence.
Frontiers in aging · Apr 2026DOI ↗ Review
This review synthesizes existing preclinical and emerging translational evidence on Thymosin β4 (Tβ4), a conserved 43-amino-acid peptide, and its N-terminal metabolite Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro), as potential therapeutic candidates in kidney disease. The authors map the intracellular and extracellular mechanisms of the Tβ4–Ac-SDKP axis, including its roles in actin sequestration, cytoprotection, anti-inflammatory signaling, and antifibrotic actions across both glomerular and tubular compartments. Evidence is evaluated across models of both acute and chronic kidney injury. The review acknowledges contradictory findings regarding fibrosis and proposes conceptual frameworks to explain bidirectional effects and model-dependent mechanisms. Translational considerations discussed include peptide pharmacokinetics, stability challenges, and drug delivery strategies. The authors note that key barriers to clinical translation remain, including the need for validation in additional clinically relevant models, resolution of peptide instability, and comprehensive safety profiling. As a narrative review, this paper does not generate new experimental data, and its conclusions are limited by the quality and heterogeneity of the underlying studies, most of which appear to be animal-based.
Review
This narrative review examines the potential role of therapeutic peptides in orthopaedic care, synthesizing preclinical and mechanistic literature across several peptide classes. The authors categorize peptides by their primary proposed function: wound-healing agents (BPC-157, TB-500, GHK-Cu), growth hormone secretagogues (ipamorelin, CJC-1295, tesamorelin, sermorelin, AOD-9604), recovery-enhancing peptides (epithalon, delta sleep-inducing peptide, pinealon), and neuroactive peptides (selank, semax, dihexa). The review describes how these compounds are theorized to interact with signaling pathways—including PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK—to promote tissue regeneration, resolve inflammation, and support neuromuscular recovery. The authors acknowledge that, while preclinical evidence is promising, robust human clinical trial data are largely absent, representing a significant gap in the literature. Limitations include the review's reliance on animal and in vitro studies, the absence of a systematic search methodology, and the lack of direct clinical evidence supporting efficacy or safety in human orthopaedic populations. The authors call for future controlled trials to validate these mechanistic findings in clinical settings.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · Jan 2026DOI ↗ Review
This narrative review, aimed at orthopaedic and sports medicine physicians, synthesizes the existing biochemical and clinical literature on six commonly marketed injectable therapeutic peptides: BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. The authors conducted a PubMed literature search and evaluated evidence across preclinical and clinical settings. Key findings attributed to the reviewed studies include: BPC-157 showed potential in tendon and muscle repair in preclinical models, with one human case series reporting pain reduction after intra-articular knee injection, though that study had significant methodological limitations and no control group. TB-4 and TB-500 demonstrated angiogenesis and tissue repair effects in animal models, but no human orthopaedic data were identified, and both are banned in sport. CJC-1295 combined with ipamorelin improved muscle tension in a murine glucocorticoid-induced muscle loss model only. Tesamorelin holds FDA approval for HIV-associated lipodystrophy but lacks orthopaedic evidence. GHK-Cu showed wound healing and anti-inflammatory properties preclinically, with no clinical musculoskeletal data. The authors conclude that indications, safety profiles, and dosing for all these peptides remain undefined for orthopaedic use, and robust human trials are needed before clinical recommendations can be made.
The American journal of sports medicine · Jan 2026DOI ↗ ReviewPreprint
This review paper examines the pharmacological mechanisms, safety profiles, and regulatory status of both approved and unapproved peptide therapies relevant to sports medicine, musculoskeletal injury recovery, and athletic performance enhancement. The compounds reviewed span a wide spectrum — from FDA-approved agents such as tesamorelin and sermorelin, to gray-market compounds including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, FS-344, GHK-Cu, MOTS-C, and SS-31. The authors note that while many unapproved peptides show promising results in preclinical and animal models — including favorable tissue repair and metabolic effects — rigorous human safety and efficacy data remain scarce. The review highlights a growing direct-to-consumer gray market operating outside regulatory oversight and discusses how social media may amplify perceived benefits through placebo-related mechanisms. The paper also offers a clinical framework to guide patient conversations and support evidence-based decision-making. Key limitations include the inherent constraints of a narrative review design, reliance on heterogeneous preclinical data for unapproved compounds, and the absence of controlled human trials for most of the highlighted peptides.
Unknown journal · Dec 2025DOI ↗ Review
This review paper surveys the current landscape of analytical methods used in sports anti-doping laboratories to detect peptide-based drugs, drug candidates, and their analogs in biological specimens such as blood, serum, and urine. The authors describe the broad range of peptidic compounds subject to anti-doping scrutiny, spanning low-molecular-mass peptides (e.g., growth hormone-releasing peptides, ARA-290, TB-500, AOD-9604, CJC-1295, desmopressin) to intermediate-mass proteins (e.g., insulins, IGF-1, growth hormone, erythropoietin) and higher-molecular-mass biologics (e.g., stamulumab). The review outlines detection approaches including chromatographic-mass spectrometric, electrophoretic, immunological, and combined methodologies, emphasizing the challenge of proving exogenous origin at very low concentrations in limited sample volumes. A central finding is that a meaningful gap remains between what is technically achievable in detection and what is routinely practiced in day-to-day analytical workflows. Limitations of this paper include its nature as a narrative review rather than an original experimental study, meaning it synthesizes existing literature without generating new empirical data. It does not evaluate clinical outcomes or therapeutic efficacy of any compound discussed.
Expert review of proteomics · Nov 2014DOI ↗ Review
This review summarizes five years of published literature on the analytical detection of emerging and non-approved performance-enhancing substances in the context of sports anti-doping controls. The authors examine a broad range of compounds classified as doping agents by the World Anti-Doping Agency (WADA), spanning both peptidic substances—such as modified insulin-like growth factor-1 (IGF-1), TB-500 (thymosin beta-4 fragment), peginesatide/hematide, growth hormone releasing peptides, and AOD-9604—and non-peptidic substances, including selective androgen receptor modulators (SARMs), hypoxia-inducible factor (HIF) stabilizers, siRNA, S-107, and aladorian (ARM036). Inorganic substances such as cobalt are also discussed. The review focuses specifically on the analytical challenges posed by these compounds, including their physicochemical properties, low concentrations in biological matrices (blood and urine), metabolic transformation, and suitability for chromatographic–mass spectrometric or alternative detection methods. The study does not present original experimental data or human clinical outcomes, but rather synthesizes existing literature to guide development of detection strategies. A key limitation is that, as a review, it does not independently validate any analytical method and reflects the state of the field only up to its publication date.
Journal of pharmaceutical and biomedical analysis · May 2014DOI ↗